|
|
|
Arava - Class Action Information
|
The Kahn Gauthier Gauthier Law Group is investigating possible lawsuits against Aventis Pharmaceuticals Inc., the
maker of the prescription arthritis drug Arava (leflunomide), following revelations that a significant number of
patients taking Arava have suffered liver damage. Due to these revelations, the highly-regarded public interest
group Public Citizen submitted a petition to the U.S. Food and Drug Administration (FDA) on March 28, 2002,
requesting that Arava be taken off the market immediately. Arava, which is classified as a DMARD (disease-modifying
anti-rheumatic drug), is prescribed for patients with active rheumatoid arthritis.
Public Citizen combed through adverse reaction reports received by the FDA and determined that, since the FDA
approved Arava on September 10, 1998, Arava has been associated with at least 130 cases of severe liver toxicity
in the U.S., including 56 hospitalizations and 12 deaths. Two of those who died were in their 20s. During the
clinical trials that led up to the approval of Arava, liver toxicity was identified as a possible side effect
of Arava.
The European Union approved Arava in September 1999, while Arava has been on the market in Canada since March 2000.
Return to Main
|
|
